


Amendments to the Claims

1. (Currently amended) A method of treating dermal lesions caused by ~~venom induced~~ venom-induced immune dysregulation, the method comprising applying a therapeutically effective amount of an immune response modifier compound selected from the group consisting of imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphthyridine amines, tetrahydroimidazonaphthyridine amines, oxazolopyridine amines, oxazoloquinoline amines, thiazolopyridine amines, thiazoloquinoline amines and 1,2-bridged imidazoquinoline amines to the site of the lesion.

2. (Original) The method of Claim 1 wherein the immune response modifier compound is a compound of Formula I



wherein

R₁ is selected from the group consisting of S and NR₃,

R₂ is selected from the group consisting of hydrogen, straight and branched chain alkyl containing one to six carbon atoms, and alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms; and

R₃ is selected from the group consisting of straight and branched chain alkyl containing one to six carbon atoms and straight or branched chain hydroxy alkyl containing one to six carbon atoms; or a pharmaceutically acceptable salt thereof.


3. (Original) The method of Claim 2 wherein R₁ is NR₃.

4. (Original) The method of Claim 2 wherein R₁ is S.

5. (Original) The method of Claim 2 wherein R₂ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, and ethoxymethyl.
6. (Original) The method of Claim 2 wherein R₃ is selected from the group consisting of 2-methylpropyl and 2-hydroxy-2-methylpropyl.
7. (Original) The method of Claim 2 wherein the IRM compound is selected from the group consisting of 4-amino-2-ethoxymethyl- α,α -dimethyl-1*H*-imidazo[4,5-*c*]quinoline-1-ethanol, 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine, 2-methylthiazolo[4,5-*c*]quinolin-4-amine, 2-ethylthiazolo[4,5-*c*]quinolin-4-amine, 2-propylthiazolo[4,5-*c*]quinolin-4-amine and 2-butylthiazolo[4,5-*c*]quinolin-4-amine.
8. (Original) The method of Claim 1 wherein the immune response modifier compound is applied via a cream or a gel.
-
9. (Currently amended) The method of claim 1 wherein the source of the ~~venom-induced~~ venom-induced immune dysregulation is an ~~arthropod~~ arthropod.
C2
10. (Currently amended) The method Claim 9 wherein the ~~arthropod~~ arthropod is a spider.
-
11. (Canceled) The method of Claim 9 wherein the arthropod is an insect of the order Hymenoptera.
12. (Canceled) The method of Claim 1 wherein the source of the venom induced immune dysregulation is a marine animal.
13. (Canceled) The method of Claim 12 wherein the marine animal is a jellyfish.
-
14. (Currently amended) A method of preventing dermonecrosis caused by ~~venom-induced~~ venom-induced immune dysregulation, the method comprising applying a therapeutically effective amount of an immune response modifier compound selected from the group consisting
C3

of imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphthyridine amines, tetrahydroimidazonaphthyridine amines, oxazolopyridine amines, oxazoloquinoline amines, thiazolopyridine amines, thiazoloquinoline amines and 1,2-bridged imidazoquinoline amines to the site of the ~~venom-induced~~ venom-induced immune dysregulation.

15. (Original) The method of Claim 14 wherein the immune response modifier compound is a compound of Formula I



wherein

R₁ is selected from the group consisting of S and NR₃,

R₂ is selected from the group consisting of hydrogen, straight and branched chain alkyl containing one to six carbon atoms, and alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms; and

R₃ is selected from the group consisting of straight and branched chain alkyl containing one to six carbon atoms and straight or branched chain hydroxy alkyl containing one to six carbon atoms; or a pharmaceutically acceptable salt thereof.

16. (Original) The method of Claim 15 wherein R₁ is NR₃.

17. (Original) The method of Claim 15 wherein R₁ is S.

18. (Original) The method of Claim 15 wherein R₂ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, and ethoxymethyl.

19. (Original) The method of Claim 15 wherein R₃ is selected from the group consisting of 2-methylpropyl and 2-hydroxy-2-methylpropyl.

20. (Original) The method of Claim 15 wherein the IRM compound is selected from the group consisting of 4-amino-2-ethoxymethyl- α,α -dimethyl-1*H*-imidazo[4,5-*c*]quinoline-1-ethanol, 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine, 2-methylthiazolo[4,5-*c*]quinolin-4-amine, 2-ethylthiazolo[4,5-*c*]quinolin-4-amine, 2-propylthiazolo[4,5-*c*]quinolin-4-amine and 2-butylthiazolo[4,5-*c*]quinolin-4-amine.

21. (Original) The method of Claim 14 wherein the immune response modifier compound is applied via a cream or a gel.

22. (Currently amended) The method of claim 14 wherein the source of the ~~venom-induced~~ venom-induced immune dysregulation is an ~~arthropod~~ arthropod.

23. (Currently amended) The method Claim 22 wherein the ~~arthropod~~ arthropod is a spider.

24. (Canceled) The method of Claim 22 wherein the arthropod is an insect of the order Hymenoptera.

25. (Canceled) The method of claim 14 wherein the source of the venom induced immune dysregulation is a marine animal.

26. (Canceled) The method of Claim 25 wherein the marine animal is a jellyfish.